Chondroblastoma

Chondroblastoma is a rare benign cartilage tumour, under 1% of all bone tumours, and the only benign cartilage tumour that arises in the epiphysis; enchondroma and osteochondroma arise in the metaphysis or diaphysis. Benign is not the same as harmless. It causes significant pain, it recurs after curettage, and in rare cases it seeds the lungs.

Who. Peak age is 10-25 years (range 5-30), with a male predominance of 2:1. In the largest multicentre series, 199 extremity chondroblastomas, the physis was already closed in 52% at presentation.

Where. Ninety-five per cent arise at the ends of long bones, and the knee accounts for roughly half (proximal tibia plus distal femur was 46.7% in the modern series). The classic list and the largest modern series disagree on the order:

• Traditional teaching, from the older Mayo material: proximal humerus 20-25%, distal femur 15-20%, proximal tibia 15-20%, proximal femur 10-15%, talus 5-10%
• The 199-case multicentre series (PMID 26041854): proximal tibia 27.6%, proximal femur 26.1%, distal femur 19.1%, with the proximal humerus well down the list
• The 87-case paediatric open-physis series (PMID 19723993) agrees, naming the proximal tibia and the proximal femoral epiphysis as commonest

Do not spend long defending either ordering: the four sites are all common. What matters clinically is that the proximal humerus was the only significant predictor of local recurrence (p = 0.001) in the 199-case series, so remember it for its risk rather than its frequency.

Rare sites. Flat bones and the spine are rarely involved; vertebral involvement was 9 of 856 cases (1.4%) in the Mayo review. Calcaneus, talus and patella are rare sites, and the atypical sites are covered under presentation.

The physis narrows the differential. Chondroblastoma arises while the physis is open, may extend into the metaphysis after physeal closure, and in rare cases extends across an open physis, which is unusual among tumours. Giant cell tumour typically presents after physeal closure, at 20-40 years. The status of the growth plate is critical to narrowing the differential:

• Epiphyseal lesion with an open physis: think chondroblastoma (or infection)
• Epiphyseal lesion with a closed physis: think giant cell tumour (or clear cell chondrosarcoma)

Histogenesis. Chondroblastoma arises from germinative cartilage cells in the epiphysis, the primitive chondroblasts that normally form secondary centres of ossification. The trigger for neoplastic transformation is unknown, but recurrent H3F3B K36M mutations are found in 95% of cases and appear to be the driver.

The mutation is somatic rather than germline, sits in the histone H3.3 variant and affects epigenetic regulation, and it can be detected with a mutation-specific antibody, which helps to separate chondroblastoma from its mimics.

Natural history. Growth is slow and progressive. In 5-10% the tumour penetrates the articular cartilage into the joint. A secondary aneurysmal bone cyst develops in a reported 15-35%. In under 1%, viable tumour cells implant in the lungs without malignant transformation, the benign metastasising chondroblastoma.

Gross pathology. The curettage specimen is friable red-grey tissue, gritty from its calcifications. The tumour is well circumscribed within the epiphysis, with cystic haemorrhagic areas where a secondary ABC is present.

Histology

Chondroblasts, the neoplastic cell. Mononuclear round to polygonal cells with distinct cell borders, pink cytoplasm and oval nuclei carrying longitudinal grooves that give a coffee-bean appearance. These are the tumour cells; everything else on the slide is a reaction to them.

Chicken-wire calcification, the pathognomonic feature. Dystrophic calcification of the pericellular (lacunar) matrix forms a lacy network of calcified rims encircling individual chondroblasts. On haematoxylin and eosin it is a fine purple-blue net outlining cells, and at low magnification it resembles chicken-wire fencing. It is this rim around single cells, and not the giant cells, that separates chondroblastoma from giant cell tumour and from every other bone tumour.

Giant cells, reactive. Osteoclast-type multinucleated giant cells are scattered through the tumour, but fewer than in giant cell tumour. They are reactive, not neoplastic, which is why counting them is the classic route to the wrong diagnosis.

Chondroid matrix, variable. Cartilaginous matrix is present focally, with chondroblasts sitting in hyaline or myxochondroid ground substance that is often calcified. Its absence does not exclude the diagnosis.

View larger

View larger

View larger

Immunohistochemistry

Secondary Aneurysmal Bone Cyst

A minority, but far from a trivial one. The reported frequency is higher when histological rather than radiographic criteria are used, which is the main reason published figures disagree. The cyst creates blood-filled spaces within the tumour, and it matters because it can:

• Obscure the underlying chondroblastoma on imaging, so the lesion appears purely cystic
• Lead to rapid expansion and pathological fracture
• Make biopsy diagnosis difficult if the solid component is not sampled

What it does not do is predict recurrence. In the paediatric multicentre series, an aneurysmal bone-cyst component on histology had no significant influence on local recurrence, and neither did sex, radiographic aggressiveness or the surgical method used. The only factor that mattered was a strictly epiphyseal location. An ABC component is a diagnostic trap, not a prognostic one.

WHO classification (2020). Chondroblastoma is listed as a benign cartilage tumour with locally aggressive (intermediate) behaviour, ICD-O code 9230/0. Its defining characteristics are the epiphyseal location, the mononuclear chondroblasts, the chicken-wire calcification pattern and the H3K36M mutation.

Enneking staging. Most chondroblastomas present as stage 2 lesions:

• Stage 1 (latent): intracapsular and well demarcated, with minimal symptoms or an incidental finding; observation may be appropriate
• Stage 2 (active): the most common presentation; symptomatic with progressive growth, but contained by natural barriers; curettage with adjuvant therapy
• Stage 3 (aggressive): breaks through the cortex or physis with extracompartmental extension; may require en bloc resection

Symptoms. A dull aching pain, worse with activity, in 90%, usually chronic over months to years. Reactive synovitis in the adjacent joint gives an effusion in 40%, with stiffness from pain and effusion, and a limp when the lower limb is involved.

Examination. Tenderness is localised to the epiphyseal region, there is an effusion from reactive synovitis, and range of motion is restricted by pain rather than a mechanical block. The joint may be warm but is not erythematous, and chronic knee pain leaves quadriceps wasting.

Typical scenarios. Each common site has a benign condition it is mistaken for:

• Proximal humerus: an adolescent athlete with shoulder pain worse on overhead activity and limited abduction and forward flexion, mistaken for rotator cuff tendinitis or impingement
• Distal femur: an adolescent with anterior knee pain and an effusion, worse running or jumping, mistaken for patellofemoral pain syndrome or Osgood-Schlatter disease
• Proximal tibia: an adolescent with knee pain localised to the proximal tibia and a common effusion, mistaken for a meniscal tear or tibial spine injury
• Proximal femur: a child or adolescent with hip pain and a limp, worse on internal rotation, mistaken for SCFE or Perthes disease

Rare presentations. When the tumour has penetrated the articular cartilage it presents with mechanical symptoms, locking and catching, mimicking a loose body or a meniscal tear, and arthroscopy shows a cartilage defect with tumour tissue. Benign pulmonary metastasis is usually asymptomatic, discovered on routine chest radiograph or CT as multiple small pulmonary nodules months to years after treatment of the primary, and may regress spontaneously.

Atypical sites. The classic teaching is the long-bone epiphysis, but chondroblastoma also arises in epiphyseal-equivalent and atypical locations, and these behave or present differently:

• Apophyses, the greater trochanter, tibial tubercle, iliac crest and patella, share the biology of an epiphyseal lesion because apophyses are secondary ossification centres; keep chondroblastoma in the differential for a lytic apophyseal lesion in a young patient
• Tarsal bones, the talus and calcaneus, present late with vague hindfoot or ankle pain, often misdiagnosed as a sprain or a simple cyst, are technically difficult to access, and carry a higher recurrence rate than long-bone lesions
• Craniofacial skeleton, classically the temporal bone and skull base, occurs in older patients than long-bone disease and presents with hearing loss, temporomandibular symptoms or a skull-base mass
• Flat and irregular bones (rib, pelvis, scapula) are rare but reported

Against giant cell tumour. Both are epiphyseal lesions with giant cells, and the table carries most of the separation: age and physeal status, the sclerotic rim and calcification that giant cell tumour lacks, and the rim around single cells rather than sheets of giant cells on the slide. Two further points. Chondroblastoma is S100 positive and giant cell tumour is S100 negative, and giant cell tumour is locally aggressive, recurring in 20-50%.

View larger

View larger

View larger

Algorithm

View larger

The decision. Extended curettage with adjuvants is the gold standard for the primary lesion, and the goal is to remove the tumour while preserving the joint and the growth plate. Wide en bloc excision is the exception, kept for:

• Recurrent chondroblastoma after failed curettage (two or more recurrences)
• Expendable bone (proximal fibula, fibular head)
• Extensive joint destruction precluding curettage
• Malignant transformation
• Proximal femur with AVN risk

Recurrence is not one number. Extended curettage with adjuvants is conventionally quoted as reducing recurrence from around 30% after simple curettage to roughly 10-20%. Treat that as received teaching rather than a proven effect: the comparison comes from historical and between-series data, never from a randomised trial.

The variable that separates the published series is skeletal maturity. In the 199-case multicentre series, 52% skeletally mature, recurrence was 5.0% after curettage and 0% after en bloc resection; in the 87-case paediatric series with every physis open it was 32%, strictly epiphyseal lesions did significantly worse (p = 0.004), and the surgical method used had no significant influence. A single-unit series of 53 sat between them at 13.2%.

Wide ExcisionSpecial ScenariosPercutaneous Ablation

Proximal fibula. The fibular head is expendable and not critical for knee stability, which makes it the ideal site for excision. En bloc resection with 5-10 mm margins, detaching biceps femoris and protecting the common peroneal nerve; no reconstruction is needed and the functional outcome is excellent.

Proximal femur. Curettage here risks avascular necrosis if the blood supply is disrupted, so wide excision with femoral head replacement is considered for recurrent disease or in the older adolescent near skeletal maturity. Wide excision means resecting the femoral head and neck and reconstructing with a modular endoprosthesis or allograft, at significant morbidity and cost.

Other sites. The proximal humerus, distal femur and proximal tibia are hard to reconstruct, so curettage is preferred even for recurrences and wide excision is kept for multiple recurrences or malignant transformation.

Malignant transformation. Extremely rare, at under 1%, and when it occurs it is usually after multiple curettages with high-dose radiation. Rapid growth after years of stability, cortical destruction with a soft-tissue mass, and high-grade chondrosarcoma or dedifferentiated areas on histology are the features. Treatment is wide excision with margins and the prognosis is poor (high-grade sarcoma). Do not irradiate chondroblastoma: radiation increases the risk of malignant transformation.

Cartilage penetration into the joint. Diagnostic arthroscopy is optional, to visualise the cartilage defect, assess the size of the penetration and debride intra-articular tumour. Definitive treatment is open curettage approached through the metaphyseal or epiphyseal cortex rather than through the joint, curetting the tumour from beneath the articular surface and preserving as much cartilage as possible; a large defect may need cartilage repair with an osteochondral graft.

A large subchondral defect is protected non-weight-bearing for 8-12 weeks, with early range of motion to prevent stiffness and monitoring for arthritis.

Benign pulmonary metastasis. The histology of the pulmonary implants is identical to the primary chondroblastoma, and they are not a malignancy.

Do Not Overtreat Pulmonary Lesions

Benign metastasising chondroblastoma does not require aggressive treatment:

• Confirm the diagnosis with biopsy if it is uncertain, to rule out metastatic sarcoma
• Observe with serial CT scans every 6 months; many lesions remain stable or regress spontaneously
• Resect only if symptomatic (rare) or progressively enlarging
• Do not give chemotherapy or radiation; the prognosis is excellent

View larger

What and where. CT-guided percutaneous radiofrequency ablation, or cryoablation, is a developing alternative to open curettage for the small chondroblastoma, typically under about 2 cm, in a deep or technically awkward site, classically the talus or the femoral head and neck, where open curettage is morbid.

It is a day-case procedure that needs no bone graft, preserves bone and recovers faster.

The caveats. It does not replace extended curettage for most accessible lesions:

• It provides no tissue diagnosis, so a confirmatory biopsy must be obtained first, ideally at the same sitting; never ablate an undiagnosed epiphyseal lesion
• Thermal injury threatens adjacent articular cartilage (chondrolysis), an open physis (growth arrest), and neurovascular structures and skin within about 1 cm, so it is avoided for subarticular lesions hugging the joint surface or lesions close to nerves unless thermoprotection (hydrodissection, gas or saline insulation) is used
• It is not suitable for larger lesions or those with a significant secondary ABC component, and incomplete ablation or recurrence may require repeat ablation or conversion to curettage

How adjuvants extend the margin. Curettes alone leave microscopic tumour on the cavity wall. The burr removes it mechanically, and a chemical or thermal adjuvant then kills cells a further millimetre or two beyond that, so the two together push the effective margin past the visible cavity in a lesion that cannot be resected because of where it sits.

Phenol, the most common adjuvant, cauterises chemically and penetrates 1-2 mm; cryotherapy ruptures cell membranes with freeze-thaw cycles; argon beam ablates the surface thermally; hydrogen peroxide is a further chemical option; and the exothermic polymerisation of PMMA reaches 60-80°C and kills cells.

Filling the void. Two options:

• PMMA cement gives mechanical support and early weight-bearing, its exothermic reaction adds an adjuvant effect, and recurrence is easier to see at the cement-bone interface
• Bone graft, autograft or allograft, is a biological reconstruction preferred in young patients, but may obscure recurrence on imaging

Subchondral bone. Preserve a minimum of 5 mm of subchondral bone if possible. Where the subchondral bone is involved, curette carefully to avoid cartilage damage and consider supporting the cartilage with bone graft, accepting the risk of future osteoarthritis if aggressive curettage is required.

View larger

Managing recurrence. The typical timeline is 1-3 years after surgery. Confirm it first with MRI and biopsy, since bone graft resorption can look the same, then escalate:

1. First recurrence: repeat extended curettage with adjuvants, which succeeds in 70-80%
2. Second recurrence: consider wide excision if feasible, in an expendable bone
3. Multiple recurrences: en bloc resection, or accept the disease and manage the symptoms

Multiple recurrences do not indicate malignant transformation; chondroblastoma is benign but can be locally persistent, and radiotherapy is avoided because of the transformation risk.

The first fortnight. Hospital stay is usually 1-2 days. Analgesia is multimodal, moving to oral medication on day 1, and NSAIDs are avoided initially for a theoretical bone healing concern. Sutures or staples come out at 10-14 days; the wound is kept dry until healed and watched for haematoma and drainage.

Weight-bearing and activity. In the lower limb, touch weight-bearing for 4-6 weeks, progressing with bone healing to full weight-bearing typically by 8-12 weeks. In the upper limb, a sling for 2-4 weeks and then range-of-motion exercises. Impact activity is avoided for 3-6 months, and return to sport waits for imaging to confirm healing.

Surveillance. Recurrence typically occurs within 2 years, and most recurrences announce themselves with a return of pain before the imaging changes. Radiographs are taken every 3 months for the first year, every 6 months in the second, then annually to 5 years; CT or MRI follows any suspicious plain film.

Rehabilitation. Range of motion is the priority, then muscle strength, then proprioception and function. The details follow the site:

• Shoulder: early passive range of motion, no heavy overhead lifting for 3 months
• Knee: quadriceps strengthening, protection from impact
• Hip: protected weight-bearing and gait training
• Ankle and talus: gradual return to weight-bearing with orthotic support

Return to sport waits for all four: imaging confirming bone healing, full pain-free range of motion, strength within 90% of the contralateral limb, and completed sport-specific rehabilitation.

The long view is excellent. With appropriate treatment 80-90% are cured by a single curettage with adjuvants, recurrences are manageable with repeat curettage or excision, and functional outcomes are excellent in most cases. The risk of degenerative arthritis is low, under 10%, if the articular surface is preserved.

What to tell the family. Chondroblastoma is benign, not cancer. One operation is curative in most, repeat surgery is effective if it recurs, long-term function and a return to sport are expected, the lifetime risk of arthritis is low if the joint surface is protected, and there is no need for lifelong surveillance after 5 years disease-free.

Global Epidemiology

Chondroblastoma is consistently reported as a rare benign bone tumour, accounting for under 1% of all primary bone tumours across published series. Demographics are stable across continents: a male predominance (roughly 2:1) and a young age at presentation. In the largest published multicentre extremity series (199 patients), the mean age was 18 years, with the proximal tibia (27.6%) and proximal femur (26.1%) the most common sites, and the physis open in 25.7%, closing in 22.2% and closed in 52.1% at presentation. In a paediatric-only multicentre cohort restricted to open physes (87 patients), the mean age was 12.5 years with the proximal tibia and proximal femoral epiphysis predominating.

Guideline & Network Positions

Practice Variation

• Adjuvant choice varies by centre and region: high-speed burr is near-universal, with phenol, cryotherapy, argon-beam or PMMA cementation selected by surgeon preference and lesion site; no head-to-head trial establishes superiority.
• Void filling differs by maturity: bone graft is favoured in skeletally immature patients to preserve biology, whereas PMMA is often chosen in older patients for immediate stability and easier surveillance of the cement-bone interface.
• Image-guided ablation (radiofrequency / cryoablation) is an emerging option for small, surgically difficult lesions in some interventional-radiology-led centres but is not yet standard of care.

Documentation & Consent (Global Best Practice)

• Record growth-plate status (open vs closed) explicitly on imaging reports — it drives the differential
• Document that the differential includes chondroblastoma, giant cell tumour and infection, and that biopsy precedes any definitive surgery
• Consent for curettage should cover recurrence (approximately 10-20% with adjuvants, higher in open-physis lesions), physeal/growth-disturbance risk (under 5%), articular damage and arthritis risk (5-10%), and phenol-related soft-tissue injury
• Counsel that wide excision is reserved for recurrent disease or expendable bone (e.g. proximal fibula)